Sanofi to acquire Dynavax for $2.2bn.

Sanofi, an R&D driven, AI-powered biopharma company, agreed to acquire Dynavax, a vaccines company with a marketed adult hepatitis B vaccine, for $2.2bn. "Dynavax enhances Sanofi's adult immunization presence by adding differentiated vaccines that complement Sanofi's expertise. Its marketed adult hepatitis B vaccine and shingles candidate bring new options to our portfolio and underscore our commitment to providing vaccine protection across the lifespan," Thomas Triomphe, Sanofi Executive Vice President, Vaccines.